Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients' satisfaction with the treatment must be taken into consideration. Individual interview with pat...

Full description

Saved in:

Bibliographic Details
Published in:	Arquivos de neuro-psiquiatria Vol. 74; no. 8; pp. 617 - 620
Main Authors:	Spessotto, Caroline Vieira, Cavalli, Hanaie, Eboni, Audred Cristina Biondo, Machado, Rafael Berlezi, Mousquer, Analara Munardi, Palazzo, Lara Both, Finkelsztejn, Alessandro, Goncalves, Marcus Vinicius Magno, Sato, Henry Koiti, Siquineli, Fabio, Fragoso, Yara Dadalti
Format:	Journal Article
Language:	English
Published:	Brazil Academia Brasileira de Neurologia - ABNEURO 01-08-2016 Academia Brasileira de Neurologia (ABNEURO)
Subjects:	acetato de glatiramer Adult cloridrato de fingolimode esclerose múltipla Female Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use interferon beta Male Multiple Sclerosis - drug therapy natalizumab NEUROSCIENCES Patient Satisfaction - statistics & numerical data PSYCHIATRY Treatment Failure interferon beta cloridrato de fingolimode multiple sclerosis interferon-beta acetato de glatiramer esclerose múltipla glatiramer acetate natalizumab fingolimod hydrochloride
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients' satisfaction with the treatment must be taken into consideration. Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs. One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability. Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0004-282X 1678-4227 1678-4227 0004-282X
DOI:	10.1590/0004-282X20160091